Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8367567 | 0.95 | GRIA1 (0.75) | GRIA1ALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL8367555 | 0.95 | GRIA1 (0.80) | GRIA1ALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL12049626 | 0.91 | GRIA1 (0.84) | GRIA1ALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL29542563 | 0.91 | GRIA1 (1.00) | GRIA1HPGDMEN1KMT2A | |
| SCHEMBL678000 | 0.91 | GRIA1 (1.00) | GRIA1HPGDMEN1KMT2A | |
| SCHEMBL31562972 | 0.91 | GRIA1 (0.84) | GRIA1ALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL8368751 | 0.88 | GRIA1 (0.71) | GRIA1 | |
| SCHEMBL8368729 | 0.87 | GRIA1 (0.69) | GRIA1ALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL8366785 | 0.87 | GRIA1 (0.69) | GRIA1 | |
| SCHEMBL8367564 | 0.87 | GRIA1 (0.69) | GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799913-B2 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799913-B2 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| WO-2004062616-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003045315-A2 | CARBONYLBENZOXAZINE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |